Regeneron beats fourth-quarter revenue estimates
Tweet
Share
E-mail
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) -Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target.
Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company's previously laid out targets in January.
Total revenue was $3.43 billion, beating analysts' estimates of $3.29 billion, according to LSEG data.
The company also said it has submitted its application to U.S. Food and Drug Administration to expand use of its eczema treatment Dupixent, in patients with a type of lung disease known as chronic obstructive pulmonary disease.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
- US manufacturing rises on front-loading of orders, but factory employment tumbles to six-year low
- Meta launches cheaper range of AI smart glasses starting at $299
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
